A DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, FIXED-DOSE PHASE III STUDY OF VILAZODONE IN PATIENTS WITH GENERALIZED ANXIETY DISORDER

BACKGROUND: Vilazodone, a selective serotonin reuptake inhibitor and 5-HT(1A) receptor partial agonist, is approved for treating major depressive disorder in adults. This study (NCT01629966 ClinicalTrials.gov) evaluated the efficacy and safety of vilazodone in adults with generalized anxiety disorde...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Depress Anxiety
Main Authors: Gommoll, Carl, Durgam, Suresh, Mathews, Maju, Forero, Giovanna, Nunez, Rene, Tang, Xiongwen, Thase, Michael E
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley & Sons, Ltd 2015
Assuntos:
Research Articles
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4676920/
https://ncbi.nlm.nih.gov/pubmed/25891440
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/da.22365
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados